Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib maintenance and re-discontinuation study in chronic-phase CML after prior failed TKI-free remission
jRCTs041190117Active, not recruiting
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ponatinib in chronic myelogenous leukemia (CML). Primary endpoint: MMR rate at 12 months of ponatinib discontinuation. Started Mar 2020; status: active, not recruiting.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCTs041190117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190117.